Gene · 6197
Papers2,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative phosphoproteomics reveals kinase-mediated regulation of OCIAD1 and its roles in mitochondrial quality control. | Front Bioinform | 2026 | 42564255 | PubTator, text mining | PubMed |
| A patent perspective of RSK inhibitors to treat cancer (2020-present). | Expert Opin Ther Pat | 2026 | 42508020 | PubTator, text mining | PubMed |
| The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas. | Expert Opin Ther Targets | 2026 | 42489440 | PubTator, text mining | PubMed |
| Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening. | ChemMedChem | 2026 | 42363227 | PubTator, text mining | PubMed |
| Meta-cancer phosphoproteomic analysis unveils association of Tau phosphosites with DNA damage response. | Front Syst Biol | 2026 | 42254072 | PubTator, text mining | PubMed |
| MEK/ERK/RSK2 positive feedback loop modulates EMT to promote migration and invasion of triple-negative breast cancer through regulating GALNT5 mRNA stability. | Carcinogenesis | 2026 | 42236296 | PubTator, text mining | PubMed |
| [Coffin-Lowry syndrome: Case report in Mexico]. | Rev Med Inst Mex Seguro Soc | 2026 | 42096245 | PubTator, text mining | PubMed |
| Benzyl-Naphthoquinones as Selective Anticancer Agents for Oral Squamous Cell Carcinoma via Apoptosis Induction. | Biomedicines | 2026 | 42072298 | PubTator, text mining | PubMed |
| RPS6KA3/RSK2-mediated phosphorylation of DRAM2 promotes lysosomal targeting and autophagic flux in melanoma. | Autophagy | 2026 | 42059423 | PubTator, text mining | PubMed |
| Challenges in Diagnosis and Management of Coffin-Lowry Syndrome-Single-Center Experience. | Diagnostics (Basel) | 2026 | 41975704 | PubTator, text mining | PubMed |
| Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines. | Chem Pharm Bull (Tokyo) | 2026 | 41850817 | PubTator, text mining | PubMed |
| Brain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases. | J Med Chem | 2026 | 41837733 | PubTator, text mining | PubMed |
| Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor. | Clin Transl Sci | 2026 | 41792865 | PubTator, text mining | PubMed |
| Defining the Active Conformation of Typical Protein Kinase Domains from Substrate-Bound PDB Structures Enables Active-State AlphaFold2 Models for All 437 Human Catalytic Protein Kinases. | bioRxiv | 2026 | 41757035 | PubTator, text mining | PubMed |
| Azole-Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review. | Pharmaceuticals (Basel) | 2026 | 41754878 | PubTator, text mining | PubMed |
| Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach. | Cancers (Basel) | 2026 | 41749868 | PubTator, text mining | PubMed |
| MicroRNA Signatures of Prostate Cancer Spheroids in Microfluidic Culture Under Hormone-Deprivation Conditions. | Bioengineering (Basel) | 2026 | 41749743 | PubTator, text mining | PubMed |
| Temporal dynamics in cancer immunotherapy: the interplay between circadian rhythms, tumor microenvironment, and immune checkpoint blockade. | J Natl Cancer Cent | 2026 | 41738042 | PubTator, text mining | PubMed |
| Agmatine suppresses the imidazoline I2 receptor/ribosomal S6 kinase 2/NF-κB signaling pathway regulating alveolar macrophage polarization and ameliorating sepsis-associated acute lung injury. | Int J Immunopathol Pharmacol | 2026 | 41728646 | PubTator, text mining | PubMed |
| Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies. | Mol Biomed | 2026 | 41692895 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6197/papers